Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue (2016 - 2024)

Rhythm Pharmaceuticals (RYTM) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $109.2 million as the latest value for Q3 2024.

  • On a quarterly basis, Non-Current Deffered Revenue rose 4.34% to $109.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $109.2 million, a 4.34% increase, with the full-year FY2023 number at $106.1 million, up 40.01% from a year prior.
  • Non-Current Deffered Revenue was $109.2 million for Q3 2024 at Rhythm Pharmaceuticals, up from $108.4 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $109.2 million in Q3 2024 to a low of $3.0 million in Q1 2020.
  • A 4-year average of $85.7 million and a median of $104.7 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 40.01% in 2023, then rose 4.34% in 2024.
  • Rhythm Pharmaceuticals' Non-Current Deffered Revenue stood at $3.0 million in 2020, then skyrocketed by 2462.01% to $75.8 million in 2022, then soared by 40.01% to $106.1 million in 2023, then increased by 2.92% to $109.2 million in 2024.
  • Per Business Quant, the three most recent readings for RYTM's Non-Current Deffered Revenue are $109.2 million (Q3 2024), $108.4 million (Q2 2024), and $107.4 million (Q1 2024).